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Objective: To examine the relationships between inhaler satisfaction, treatment compliance
and health status in patients with chronic obstructive pulmonary disease (COPD).
Methods: In a large, multinational, cross-sectional, real-world survey, respiratory specialists
and primary care physicians provided information on six consecutive patients with COPD,
who were then asked to complete a questionnaire. Physician-assessed compliance was scored
(5-point Likert scale) and patients rated overall satisfaction with their maintenance inhaler
(7-point Likert scale). Health status assessments included frequency of exacerbations and hos-
pitalizations due to exacerbations in the past 12 months.
Results: The analysis included 1443 patients (71.8% male; mean age 65.2 years). Patients’
overall satisfaction with their inhaler was significantly associated with treatment compliance
(c2  df Z 89.7; p < 0.001). Male gender (c2  df Z 2.9; p < 0.05) and fewer maintenance
drugs (c2  df Z 17.7; p < 0.001) were also associated with compliance; age and breathless-
ness severity were not. Attributes influencing inhaler satisfaction mainly related to durability,
ergonomics and ease of use. Small but statistically significant associations were observed be-
tween increasing treatment compliance and fewer exacerbations (R2Z 0.037; p < 0.001) and
fewer hospitalizations due to exacerbations (R2Z 0.025; p < 0.001). There was a direct asso-
ciation between inhaler satisfaction and fewer exacerbations (R2 Z 0.03; p < 0.001).484 472 783; fax: þ44 1484 472 182.
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Inhaler satisfaction and compliance in COPD 359Conclusions: Treatment compliance appears to be modestly associated with inhaler satisfac-
tion, better health status and less frequent COPD exacerbations, although other factors are
also likely to be involved. Durability, ergonomics and ease-of-use are inhaler attributes that
influence patient satisfaction.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a com-
mon, usually progressive respiratory disease characterized
by persistent airflow limitation [1]. COPD is a major cause
of morbidity and mortality globally and is associated with
significant economic and social burden [1].
Inhaled medications, including short- and long-acting
bronchodilators and corticosteroids, are central to COPD
therapy [1]; however, in order to achieve maximal clinical
benefit, it is important that patients are able to use their
inhaler devices correctly and that they adhere to pre-
scribing instructions [2e5]. In common with other chronic
diseases, adherence to or compliance with prescribed
therapies has been widely reported to be suboptimal in
patients with COPD [2,4e8]. Between 40% and 60% of pa-
tients with COPD do not adhere to their prescribed medi-
cations and between 4% and 95% of patients fail to use their
inhalers correctly, depending on inhaler type and assess-
ment method [3,5,9].
Patients with COPD may be prescribed a number of
separate inhalers for the delivery of short-term relief
medications and maintenance therapy, each requiring
different techniques. Ensuring that patients are able to use
their different inhaler types correctly may be an important
strategy to increase patient satisfaction and, consequently,
improve treatment compliance and clinical outcomes in
COPD. However, whilst compliance has been reported to be
positively influenced by inhaler satisfaction in patients with
asthma [10e13], there is a lack of data demonstrating a
causal relationship in COPD [14].
Using data from the Adelphi Respiratory Disease Specific
Programme (DSP; Adelphi, Macclesfield, UK), the objec-
tives of the analysis reported in this paper were to identify
the factors, including patient characteristics and patient-
reported inhaler satisfaction, which are significantly asso-
ciated with treatment compliance, to examine the influ-
ence of specific inhaler attributes that contribute to overall
inhaler satisfaction, to report on the relationships between
compliance and health status and resource use, and to
explore the direct association of inhaler satisfaction with
health status.
Methods
Study design
The Respiratory DSP was a large, cross-sectional survey of
real-world clinical practice that was conducted in France,
Germany, Italy, Spain and the UK between June and
September 2009, as reported in detail elsewhere [15].
Respiratory specialists and primary care physicians wereidentified locally, from public lists of healthcare pro-
fessionals, to provide a sample of physicians that was
representative of healthcare professionals managing pa-
tients with COPD in each participating country. A pragmatic
sample size was used, consistent in each country. Propor-
tional stratification sampling was not implemented. In
order to avoid selection bias, a proportionately larger
sample of physicians was identified in areas of high popu-
lation density than in areas of low population density.
Eligibility was determined based on specialty, personal
responsibility for treatment decisions and number of pa-
tients with COPD seen in a typical week. Eligible physicians
who accepted an invitation to participate in the study were
asked, via patient record forms, to provide information on
their next six consecutive patients consulting with COPD (as
confirmed by participating physicians), who had airflow
obstruction, were aged at least 40 years and had a history
of smoking. These patients were then invited by the
physician to independently and voluntarily complete a
confidential questionnaire (patient self-completed form),
which was returned in a sealed envelope.
The Respiratory DSP was conducted in accordance with
the European Pharmaceutical Market Research Association
(EphMRA) code of conduct for international healthcare
market research [16], and all participating patients pro-
vided informed consent. Ethical approvals were, therefore,
not required. To ensure compliance with data protection
laws, all data were de-identified and aggregated prior to
receipt by Adelphi Real World.
Physician-reported variables
Physician-reported data included patient demographics and
disease characteristics. COPD severity was reported based
on physicians’ clinical judgment, which may have consid-
ered other information in the patients’ medical records in
addition to spirometry findings. Additionally, the modified
Medical Research Council (mMRC) dyspnea scale [17] was
used to measure the level of patient breathlessness on a
scale from 0 (‘only gets breathless after exercising heavily’)
to 4 (‘too breathless to leave the house’). The number of
COPD exacerbations experienced by patients in the past 12
months was also recorded with details of where they were
managed (primary care, emergency room or hospitaliza-
tion). For the purposes of this study, an exacerbation was
defined as a worsening of COPD symptoms that could not be
brought under control by relief medication.
Treatment compliance was defined as the extent to
which patients were assessed by their physician to follow
their prescribing instructions and advice. It was rated by
physicians, based on perceived frequency of medication
administrations per day, using a 5-point Likert scale,
360 H. Chrystyn et al.whereby 1 indicated ‘not at all compliant’ and 5 indicated
‘fully compliant’.
Patient-reported variables
Patients were asked to rate their overall level of satisfac-
tion with their COPD maintenance inhaler, and with 13
specific inhaler attributes (Table 1), using a 7-point Likert
scale, whereby a score of 1 indicated ‘not at all satisfied’
and a score of 7 indicated ‘very satisfied’.
Health-related quality of life (HRQoL) was assessed using
a component of the EuroQoL-5 dimensions (EQ-5D) instru-
ment [18], in which generic health status was assessed
across five domains (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) and responses
were converted to a corresponding utility index score
(range 0.594 [worst possible] to 1.0 [best possible]).
Sleep quality was evaluated using the Jenkins Sleep
Questionnaire, [19] which recorded how often patients had
trouble falling asleep, woke several times during the night,
had trouble staying asleep and woke after a usual amount
of sleep feeling tired. The frequency of sleep disruptions
experienced by patients during the past 4 weeks was
measured on a scale from 0 (0 days) to 5 (22e28 days) for all
four items and an overall score (range 0 [best possible] to
20 [worst possible]) was calculated.
Statistical analysis
Physician- and patient-reported variables were summarized
descriptively. Patient responses were matched to physiciansTable 1 Specific inhaler attributes rated by patients.
Number Attribute
1 It is built to last and will not break easily
2 It is easy to hold and carry
3 The instructions are simple and easy to follow
4 No need for me to put the drug into the inhaler
before I use it
5 I do not need to breath in at the same time as
I press my inhaler
6 I do not need to breath in hard to inhale my
medication
7 I get the same amount of medication delivered
to my lungs each time
8 It tells me when my dose of medication has
been inhaled correctly
9 It tells me how many doses of my medication
I have left
10 It does not need to be cleaned
11 The inhaler locks when it is empty so I cannot
use it anymore
12 I can throw the inhaler away and get a new
one with each prescription
13 I keep the inhaler and refill it myself with
each prescription
Patient satisfaction with thirteen specific inhaler attributes was
rated using a 7-point Likert scale (1 Z ‘not at all satisfied’;
7 Z ‘very satisfied’).via patient/physician study numbers and the relationship
between patient-reported inhaler satisfaction and
physician-assessed compliance was analyzed using ordinary
least-squares regression. This relationship was further
investigated using a generalized additive model with no
assumptions made for the shape of the association.
Furthermore, sequential regression with average over or-
derings and bootstrap confidence intervals [20] was used to
investigate the relationship between overall inhaler satis-
faction and specific inhaler attributes. This method was
considered appropriate for a situation where the variables
in the regression were likely to be highly correlated.
The relationships between treatment compliance and
outcomes data were analyzed using generalized additive
models, with no assumptions made about the shape of the
relationship. Additive multinomial logistic regression was
also used to investigate the association of compliance with
level of breathlessness, as measured using the mMRC dys-
pnea scale. Additionally, the direct link between inhaler
satisfaction and certain outcomes (EQ-5D utility index and
number of exacerbations in the past 12 months) was also
explored using generalized additive models.
Results
Study population
A total of 679 physicians participated in the survey,
providing record forms on 2922 patients. Of these, 1718
patients returned a patient self-completed form and 1443
patients were included in the analysis. Records from the
remaining 275 patients were excluded from the analysis as
a result of missing data or patients self-reporting that they
did not use a maintenance inhaler. The sample analyzed
included a similar proportion of primary care physicians and
respiratory specialists (Table 2).
Demographics and characteristics of the study popula-
tion are summarized in Table 2. Patients with COPD ranging
in physician-observed severity from mild (approximately
25%) to very severe (approximately 6%) were included;
almost 50% of patients were reported to have moderate
disease. The majority of patients were male (71.8%) and
aged over 55 years (83.4%); mean age was 65.2 years. In
total, 1706 exacerbations were reported by 714 patients;
376 of these exacerbations resulted in hospitalization.
Relationship between inhaler satisfaction and
treatment compliance
The majority of patients were more satisfied with their
inhaler than not: 75% reported an overall satisfaction score
of at least 5 on the 7-point scale (1Z ‘not at all satisfied’;
7 Z ‘very satisfied’) (Table 3). Almost 10% were ‘very
satisfied’ with their inhaler and only 1 patient (0.1%) was
‘not at all satisfied’. The principal inhaler attributes influ-
encing overall patient satisfaction were whether it was
built to last and would not break easily, whether it was easy
to hold and carry, and whether the instructions were simple
and easy to follow (Fig. 1).
Physicians assigned a treatment compliance score of at
least 3 points on the 5-point scale (1 Z ‘not at all
Table 2 Patient distribution, demographics and disease
characteristics.
Patients
Country, n (%), N Z 1443
France 379 (26.3)
Germany 432 (29.9)
Italy 245 (17.0)
Spain 307 (21.3)
United Kingdom 80 (5.5)
Physician speciality, n (%), N Z 1443
Primary care physician 760 (52.7)
Respiratory specialista 683 (47.3)
Mean age (range), years, N Z 1443 65.2 (40e90)
Male gender, n (%), N Z 1442 1035 (71.8)
Race, n (%), N Z 1427
Caucasian 1352 (94.7)
Afro-Caribbean 25 (1.8)
Hispanic 39 (2.7)
Other 11 (0.8)
Current smokers, n (%), N Z 1423 497 (34.9)
Post-bronchodilator FEV1, mean
% predicted (SD), N Z 582
6.3. (17.0)
Physician-observed COPD severity,
n (%), N Z 1417
Mild 350 (24.7)
Moderate 658 (46.4)
Severe 328 (23.1)
Very severe 81 (5.7)
mMRC dyspnea scale scoreb,
mean (SD), N Z 1434
1.7 (1.2)
Jenkins Sleep Indexc, mean (SD),
N Z 1426
5.4 (4.3)
EQ-5D scored, mean (SD), N Z 1437 0.7 (0.3)
COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQoL-
5 dimensions; FEV1, forced expiratory volume in 1 second;
mMRC, modified Medical Research Council; SD, standard
deviation.
a Pulmonologist or equivalent in each country.
b Scale: 0 Z ‘only gets breathless after exercising heavily’ to
4 Z ‘too breathless to leave the house’.
c Range: 0 (best possible) to 20 (worst possible).
d Range: 0.594 (worst possible) to 1.0 (best possible).
Table 3 Patient-reported overall inhaler satisfaction and
physician-assessed compliance scores.
Patients, n (%)
Patient-reported level of overall inhaler satisfaction,
N Z 962
1 (not at all satisfied) 1 (0.1)
2 8 (0.8)
3 49 (5.1)
4 182 (18.9)
5 333 (34.6)
6 294 (30.6)
7 (very satisfied) 95 (9.9)
Physician-assessed compliance, N Z 1428
1 (not at all compliant) 10 (0.7)
2 95 (6.6)
3 292 (20.4)
4 551 (38.6)
5 (fully compliant) 480 (33.6)
Patient-reported overall inhaler satisfaction was rated using a
7-point Likert scale.
Physician-assessed compliance was rated using a 5-point Likert
scale.
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tients (Table 3). Approximately one-third of patients were
assessed as being ‘fully compliant’ whilst less than 1% was
‘not at all compliant’. Findings were similar when analyzed
by physician specialty, although a slightly greater propor-
tion of patients were considered to be ‘not at all compliant’
by respiratory specialists (n Z 8/674, 1.19%) than by pri-
mary care physicians (n Z 2/754, 0.27%). There was no
significant difference between primary care physician-
assessed and respiratory specialist-assessed compliance
(p Z 0.914).
As shown in Fig. 2, multiple regression analysis demon-
strated a statistically significant association between
patient-reported overall satisfaction with their mainte-
nance inhaler and treatment compliance (c2  df Z 89.7;
R2 Z 0.087, p < 0.001). Other factors associated with
higher compliance scores, though to a lesser degree, werelower number of maintenance drugs (c2  df Z 17.7;
p < 0.001) and male gender (c2 df Z 2.9; p < 0.05). No
significant associations with compliance were observed for
either level of breathlessness or age.
Relationship between treatment compliance and
measures of health status and resource utilization
Higher treatment compliance scores were modestly asso-
ciated with fewer total exacerbations in the previous 12
months (p < 0.001) and fewer hospitalizations due to ex-
acerbations in the previous 12 months, as indicated by low
but statistically significant R2 values (R2 Z 0.037 and
R2 Z 0.025, respectively; p < 0.001 for both; Fig. 3).
Similarly, patients with higher compliance scores re-
ported better HRQoL and sleep quality, as demonstrated by
weak yet statistically significant associations with higher
EQ-5D utility index scores (R2 Z 0.035; p < 0.0001) and
lower Jenkins Sleep Index (R2 Z 0.064; p < 0.0001).
Increasing compliance was also associated with lower
mMRC dyspnea scores (R2 Z 0.031; p < 0.0001), including
greater probability of only getting breathless after exer-
cising heavily (p Z 0.0028) and lower probability of stop-
ping for breath after walking a few minutes, even on level
ground (p < 0.0001) (Table 4). There was no significant
association between compliance and walking slower than
most people of the same age. Patients with greater
compliance tended to see their respiratory specialist phy-
sicians more frequently but not their primary care physi-
cians (Table 4).
In addition, greater patient satisfaction with their
inhaler device was found to be directly associated with
higher EQ-5D utility index score (R2Z 0.03, p < 0.001) and
with significantly fewer COPD exacerbations in the previous
12 months (Fig. 4).
Figure 1 Association of overall inhaler satisfaction with specific inhaler attributes.
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Effective management of COPD to control symptoms and
reduce exacerbations is partly dependent on patient
compliance with, or adherence to, inhaled medications
[4,5]. However, incorrect inhaler technique and poor
adherence have been widely reported among patients with
COPD [2e9]. In patients with asthma, regular use of medi-
cations and adequate adherence have been shown to be
associated with improved symptom control and health
status compared with irregular use or suboptimal adher-
ence [21,22]. Additionally, patient adherence has been
reported to be positively influenced by ease-of-use andFigure 2 Relationship between patient-rated inhaler satis-
faction and physician assessed treatment compliance.patient satisfaction with their treatments [10e13]. How-
ever, to date the impact of inhaler preference or patient
satisfaction with their inhaler on adherence and clinical
outcomes in COPD has been less well investigated. This
analysis of real-world data from the Respiratory DSP
aimed to examine the relationships between patient-
reported satisfaction with their COPD maintenance
inhaler, physician-assessed treatment compliance and
health status.
Our findings demonstrate an association between overall
inhaler satisfaction and treatment compliance but do not
exclude the role of other numerous and interplaying factors
that have the potential to influence compliance in patients
with COPD. These may include patient-related factors, such
as cognitive ability, perceived efficacy and conscientious-
ness; societal factors, such as patienteprescriber rela-
tionship, inhaler instruction and follow-up; and treatment-
related factors, such as method of administration, dosing
regimen and side effects [4,5,14,23,24]. Additionally,
compared with asthma, patients with COPD are typically
older and more likely to suffer from impaired mental or
physical functioning, and multiple comorbidities, such as
arthritis, osteoporosis, cardiovascular disease, diabetes
and depression [25e27], which can necessitate complex
medication regimens and contribute to poor adherence.
Our findings also suggest that there are modest re-
lationships between greater treatment compliance and
improved health status and outcomes in patients with
COPD, including less frequent exacerbations and hospitali-
zations due to exacerbations, improved dyspnea and
HRQoL, and fewer sleep interruptions. However, these
findings should be interpreted with caution given the weak
nature of the associations observed. As this analysis
included patients with COPD of any severity (as determined
by physicians), it is possible that better compliance among
patients with mild disease, i.e. who are likely to have
Figure 3 Relationship between physician-assessed compli-
ance and (a) total number of chronic obstructive pulmonary
disease exacerbations and (b) hospitalizations due to
exacerbations.
Inhaler satisfaction and compliance in COPD 363required fewer medications and to have experienced fewer
exacerbations, may have contributed to our results. Simi-
larly, while overall inhaler satisfaction was found to be
directly associated with better health status in this anal-
ysis, namely improved EQ-5D utility index score and fewer
exacerbations, this finding is considered likely to have been
influenced by the frequency of exacerbations experienced
by the patient, as well as other factors such as patient-
ephysician relationship.
The possibility of unmeasured or unrecognized con-
founding factors is a typical limitation of observational
studies and, in the case of this analysis, the role of factors
such as inhaler technique and treatment efficacy were
also not considered. As the concepts of satisfaction with
an inhaled therapy and satisfaction with an inhaler devicemay seem interchangeable to some patients, perceived
treatment efficacy is likely to have influenced both
inhaler satisfaction and compliance to some degree.
Other limitations of this study are typical of observational
studies and include the potential bias introduced by a
reliance on participating physicians to select patients and
their judgment in the assessment of disease characteris-
tics and outcomes, and an inability to demonstrate a
causal effect of compliance on health status due to
the cross-sectional design of the survey. Furthermore,
assessing treatment compliance or adherence in chronic
diseases, including COPD, is rendered challenging by the
lack of an accepted definition and agreement on what
constitutes an acceptable level of adherence to maintain
therapeutic efficacy [4,14]. As the cross-sectional, real-
world nature of the Respiratory DSP did not allow for
compliance to be measured prospectively, it was defined
in this analysis as the extent to which patients were
assessed by their physician to follow their prescribing in-
structions and advice, as measured using a 5-point Likert
scale. The findings reported here in patients with COPD
are consistent with a similar analysis in patients with
asthma, where inhaler satisfaction was also found to be
positively associated with better health status via its
relationship with improved compliance [11]. This
approach has the advantage of allowing physicians to
compare compliance in a real-world setting relative to
their other patients. However, physician estimates of
adherence, which are subject to bias, have been reported
to be unreliable elsewhere [24,28] and this is acknowl-
edged to be another limitation of the present analysis.
Nevertheless, observational studies provide useful infor-
mation to supplement randomized, controlled trials and
the real-world, cross-sectional study reported in this
paper provides a robust, independent and impartial
portrait of current treatment practice and our findings
provide an objective perspective on the role of inhaler
satisfaction on treatment compliance in patients with
COPD.
Our results indicate that patient satisfaction with their
maintenance inhaler device is an important factor driving
treatment compliance in COPD, with a greater influence
than number of concomitant maintenance drugs, age or
severity of breathlessness. Consistent with observations
from other studies which evaluated patient preference for
different inhaler types [29e33], the inhaler features that
were most important in determining patient satisfaction in
the present analysis related to durability, ergonomics and
ease of use.
The prevalence of COPD is expected to increase in
coming years and, by 2030, it is predicted that COPD will be
the third-leading cause of death globally [34]. As a
cornerstone of COPD maintenance therapy, it will be
increasingly important to identify and address poor
compliance and adherence with inhaled respiratory medi-
cations. In addition to other strategies, such as simplifying
treatment regimens, patient education and enhanced
physician instruction and communication [4], this analysis
highlights the importance of considering patient prefer-
ences and ensuring patient satisfaction with the inhaler
used to deliver respiratory medications in order to improve
clinical outcomes.
Table 4 Relationship between increasing physician-assessed compliance scores and health status, sleep quality and
breathlessness.
Outcome Association with increasing compliance
score
N R2 p-value
Higher EQ-5D utility index scorea 1422 0.035 <0.0001
Lower Jenkins Sleep Indexa 1402 0.064 <0.0001
Lower mMRC dyspnea scale scoreb 1419 0.031 <0.0001
‘Only gets breathless after exercising heavily’ 1419 e 0.0028
‘Gets breathless when hurrying on level ground or walking up slight incline’ 1419 e 0.0522
‘Walks slower than most people of the same age’ 1419 e 0.2458
‘Stops for a breath after walking a few minutes, even on level ground’ 1419 e <0.0001
‘Too breathless to leave the house’ 1419 e 0.00016
Higher number of visits to primary care physician in past 3 monthsa 1428 0.002 0.014
Higher number of visits to specialists in past 3 monthsa 1428 0.031 <0.001
Coefficient of determination (R2) derived from generalized additive models.
EQ-5D, EuroQoL-5 dimensions; mMRC, modified Medical Research Council.
a Patient-reported.
b Physician-reported.
Figure 4 Relationship between inhaler satisfaction and
number of chronic obstructive pulmonary disease exacerba-
tions in the past 12 months.
364 H. Chrystyn et al.Conclusions
The findings of this real-world analysis suggest that, for
patients with COPD, inhaler durability, ergonomics and
ease of use are key features associated with overall main-
tenance inhaler satisfaction, and that there is a relation-
ship between inhaler satisfaction and treatment
compliance. These results also suggest that, among other
factors, there is a modest relationship between greater
treatment compliance and improved health status,
including fewer exacerbations and better HRQoL.Statement of interests
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